Cooley's Anemia Foundation

Savoy Foundation's 26th Annual Charity Gala - Royal Savoy Ball - to Benefit Children's Charities and Commemorate Her Late Majesty Queen Elena of Italy

Retrieved on: 
Friday, August 4, 2023

NEW YORK, Aug. 4, 2023 /PRNewswire-PRWeb/ -- The American Foundation of Savoy Orders, Inc. (Savoy Foundation) announces its 26th annual Ballo di Savoia (Royal Savoy Ball) on Saturday, December 9, 2023 in New York City under the patronage of Their Royal Highnesses Prince Victor Emmanuel and Princess Marina of Savoy. H.R.H. Prince Emmanuel Philibert of Savoy, Prince of Venice and Prince of Piedmont, will be the guest of honor. H.R.H. Prince Dimitri of Yugoslavia will also attend the white tie, winter charity gala supported by prominent business and community leaders and members and friends of the Dynastic Orders of the Royal House of Savoy. More than 300 guests are expected to attend the charity fundraiser at The University Club in New York City, which last year raised more than $100,000. The winter charity gala will celebrate also the 150th anniversary of the birth of Elena of Montenegro, Queen of Italy, who was renowned for her selfless dedication to many charitable causes, relief efforts and welfare initiatives which earned her the admiration and love of the Italian nation.

Key Points: 
  • The winter charity gala will celebrate also the 150th anniversary of the birth of Elena of Montenegro, Queen of Italy who was renowned for her selfless dedication to many charitable causes and welfare initiatives.
  • The charity gala will raise funds for the Foundation's mission– Chivalry for Children's Causes™ – benefiting Cooley's Anemia Foundation and A Chance in Life Organization.
  • NEW YORK, Aug. 4, 2023 /PRNewswire-PRWeb/ -- The American Foundation of Savoy Orders, Inc. (Savoy Foundation) announces its 26th annual Ballo di Savoia (Royal Savoy Ball) on Saturday, December 9, 2023 in New York City under the patronage of Their Royal Highnesses Prince Victor Emmanuel and Princess Marina of Savoy.
  • Prior to Saturday's evening Gala, a reception on Friday evening, December 8 at the Lotos Club will be held for guests attending the Royal Savoy Ball.

Savoy Foundation Presents Grants Totaling $102,000 to A Chance In Life and Cooley's Anemia Foundation

Retrieved on: 
Tuesday, April 11, 2023

NEW YORK, April 11, 2023 /PRNewswire-PRWeb/ -- The American Foundation of Savoy Orders, Incorporated (AFSO) presented grants totaling $102,000 to two designated charities which serve at-risk children on Staten Island and children with the thalassemia genetic blood disorder. The funds were primarily raised at the 25th annual Ballo di Savoia (Royal Savoy Ball) benefit gala held on December 17, 2022, in New York City at the University Club. Friends of the American Foundation of Savoy Orders, a non-profit organization, generously supported the 25th annual white-tie fundraising benefit, which welcomed 300 guests, including members of the American Delegation of Savoy Orders and international business and philanthropic leaders. Honored guests were H.R.H. Prince Emmanuel Philibert of Savoy and H.R.H. Prince Dimitri of Yugoslavia.

Key Points: 
  • The fundraising efforts were distributed on April 4, 2023 to representatives of A Chance In Life -The Village and Cooley's Anemia Foundation (CAF).
  • The Savoy Foundation awarded a $42,000 grant to A Chance In Life to support its first US-based program in New York City - A Chance in Life – The Village.
  • Gabriele Delmonaco, President and CEO and Claire Gallagher, Vice President of Development of A Chance In Life accepted the grant from Savoy Foundation President Joseph Sciame.
  • Businesses, individuals and organizations can donate here and find additional information about Savoy Foundation events and programs.

Savoy Foundation Celebrates the 25th Annual Savoy Ball Charity Gala in New York City with a Benefit for Cooley's Anemia Foundation and A Chance in Life Organization

Retrieved on: 
Thursday, August 11, 2022

NEW YORK, Aug. 10, 2022 /PRNewswire-PRWeb/ -- The American Foundation of Savoy Orders, Inc. (Savoy Foundation) will host its 25th annual Ballo di Savoia (Royal Savoy Ball) on Saturday, December 17, 2022 in New York City under the patronage of Their Royal Highnesses Prince Victor Emmanuel and Princess Marina of Savoy. H.R.H. Prince Emmanuel Philibert of Savoy, Prince of Venice and Prince of Piedmont, will be the guest of honor. H.R.H. Prince Dimitri of Yugoslavia will also attend the white tie, red carpet charity event, supported by members and friends of the Dynastic Orders of the Royal House of Savoy, which will bring together about 300 guests at a new venue, The University Club in New York City. The winter charity gala will celebrate two milestones: the 25th Silver Anniversary of the Royal Savoy Ball and the 450th Anniversary of the Order of Saints Maurice and Lazarus, founded in 1572.

Key Points: 
  • The charity gala will raise funds for the Foundation's mission Chivalry for Children's Causes benefiting Cooley's Anemia Foundation and A Chance in Life Organization.
  • NEW YORK, Aug. 10, 2022 /PRNewswire-PRWeb/ -- The American Foundation of Savoy Orders, Inc. (Savoy Foundation) will host its 25th annual Ballo di Savoia (Royal Savoy Ball) on Saturday, December 17, 2022 in New York City under the patronage of Their Royal Highnesses Prince Victor Emmanuel and Princess Marina of Savoy.
  • Prince Emmanuel Philibert of Savoy, Prince of Venice and Prince of Piedmont, will be the guest of honor.
  • The program is made possible thanks to generous support from the members and friends of the American Delegation of Savoy Orders.

First Thalassemia Patient Elected National President of Cooley's Anemia Foundation

Retrieved on: 
Wednesday, April 27, 2022

NEW YORK, April 27, 2022 /PRNewswire-PRWeb/ -- History was made today at the annual board meeting of the Cooley's Anemia Foundation (CAF) when Ralph Colasanti was elected the first person with thalassemia to serve as National President of the Foundation's board of directors. The Foundation, which was started in 1954, is the primary voice for those with thalassemia, a group of genetic disorders, one of which is also called Cooley's anemia. People with severe forms of the disease require lifelong blood transfusions as often as every 2 weeks and often beginning in infancy.

Key Points: 
  • History was made today at the annual board meeting of the Cooley's Anemia Foundation (CAF) when Ralph Colasanti was elected the first person with thalassemia to serve as National President of the Foundation's board of directors.
  • The Foundation, which was started in 1954, is the primary voice for those with thalassemia, a group of genetic disorders, one of which is also called Cooley's anemia.
  • The Cooley's Anemia Foundation is dedicated to serving people afflicted with various forms of thalassemia, most notably the major form of this genetic blood disease, Cooley's anemia/thalassemia major.
  • Every day, we strive for longer and healthier lives for all patients with thalassemia until a universal cure is found.

15th Annual Invest in Others Awards Honor Financial Advisors for Philanthropy

Retrieved on: 
Friday, September 24, 2021

ANDOVER, Mass., Sept. 24, 2021 /PRNewswire/ --The Invest in Others Charitable Foundation ("Invest in Others") presented four awards from September 20 to September 23 as part of its 15th annual Invest in Others Awards celebration, which was held virtually this year.

Key Points: 
  • ANDOVER, Mass., Sept. 24, 2021 /PRNewswire/ --The Invest in Others Charitable Foundation ("Invest in Others") presented four awards from September 20 to September 23 as part of its 15th annual Invest in Others Awards celebration, which was held virtually this year.
  • The Invest in Others Awards recognize financial advisors across four distinct categories for giving back to nonprofits in their communities.
  • Top sponsors included Advisor Group, Cetera Financial Group, Fidelity Investments, LPL Financial, Merrill, and Natixis Investment Managers.
  • The inspiration for the Invest in Others Charitable Foundation came directly from the financial advisors who invest in others by giving back to their communities with overwhelming generosity and dedication.

CAF President Peter Chieco Selected as Finalist for Lifetime Achievement Award by Invest in Others Charitable Foundation

Retrieved on: 
Thursday, July 15, 2021

NEW YORK, July 15, 2021 /PRNewswire-PRWeb/ -- Cooley's Anemia Foundation congratulates Peter Chieco, CAF Volunteer National President, on being selected as one of three national finalists for the Lifetime Achievement Award as part of the 15th Annual Invest in Others Awards.

Key Points: 
  • NEW YORK, July 15, 2021 /PRNewswire-PRWeb/ -- Cooley's Anemia Foundation congratulates Peter Chieco, CAF Volunteer National President, on being selected as one of three national finalists for the Lifetime Achievement Award as part of the 15th Annual Invest in Others Awards.
  • Mr. Chieco's decades of work on behalf of the Cooley's Anemia Foundation has gained him this unique honor, and as a result, CAF will receive a $20,000 donation from the Invest in Others Charitable Foundation.
  • Notably, Mr. Chieco developed CAF's first endowment campaign, which provided the Foundation with financial stability during the COVID pandemic.
  • CAF National Executive Director Craig Butler commented, "The Cooley's Anemia Foundation is thrilled that Invest in Others Charitable Foundation has recognized the extraordinary work and dedication of Peter Chieco, our National President and a long-time member of the CAF Board of Directors.

Thalassemia Pipeline 2020 with Detailed Analysis of 37 Companies - ResearchAndMarkets.com

Retrieved on: 
Monday, July 27, 2020

The "Thalassemia Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thalassemia Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
  • Thalassemia is one of the widely researched conditions during 2020 with 37 companies actively focusing on realizing pipeline's potential.
  • The Thalassemia pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
  • The competitive intelligence report on Thalassemia presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Thalassemia pipeline.

Aruvant Appoints Joseph McIntosh, M.D. as Chief Medical Officer

Retrieved on: 
Monday, May 11, 2020

as chief medical officer effective immediately.

Key Points: 
  • as chief medical officer effective immediately.
  • With 16 years of drug development experience, including more than a decade in rare disease, Dr. McIntosh will oversee clinical development at Aruvant.
  • His initial focus will be the clinical program for ARU-1801, a one-time, potentially curative gene therapy for patients with sickle cell disease and -thalassemia.
  • "Dr. McIntosh's extensive experience in rare disease and gene therapy will be invaluable as we advance the clinical development of our potentially curative gene therapy ARU-1801," saidWill Chou, M.D., Chief Executive Officer ofAruvant.

2020 Thalassemia Pipeline Insights Report: Therapeutic Assessment, Product Stages & Profiles, Unmet Needs, Patents & Companies - ResearchAndMarkets.com

Retrieved on: 
Monday, April 20, 2020

Thalassemia Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Thalassemia market.

Key Points: 
  • Thalassemia Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Thalassemia market.
  • A detailed picture of the Thalassemia pipeline landscape is provided, which includes the disease overview and Thalassemia treatment guidelines.
  • The report provides insights into:
    All of the companies that are developing therapies for the treatment of Thalassemia with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Thalassemia treatment.